Daiichi Sankyo poised to enter Japan's generics sector
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is to set up a new operation in Japan for the manufacture and marketing of its own mature products as well as generics sourced from Ranbaxy Laboratories, in a move designed to build on its 2008 acquisition of the Indian firm.